SloveniaNovartis has returned to the sale of products, but its profits remain under pressure from generic drugs. The article discusses the impact of generic drug competition on Novartis' financial performance, highlighting ongoing challenges in maintaining profitability despite strategic adjustments.
Bias read (Center): The headline focuses on a business-related issue involving pharmaceutical sales and profit pressures from generic drugs. There is no indication of political framing, bias, or controversy in the limited information provided. The content appears neutral and factual.
